KLOW vs GLOW Peptide Blend: What Adding KPV Actually Changes

October 9, 2026

KLOW is GLOW plus one extra peptide. GLOW combines GHK-Cu, BPC-157 and TB-500 in one lyophilized vial. KLOW adds KPV, a three-amino-acid fragment of alpha-MSH, as a fourth component.

That single addition changes three things: the blend’s research focus, its regulatory picture after the July 2026 FDA panel vote, and how much you need to check on its certificate of analysis (COA). This guide covers all three. If you’re new to the three-peptide version, start with our GLOW blend explainer.

What is the GLOW peptide blend?

GLOW is a three-peptide research blend supplied as a single lyophilized powder. Each component has its own, separate body of preclinical literature:

GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It is the reason GLOW powder has a blue tint. Our GHK-Cu guide covers its structure and history.
BPC-157 is a 15-amino-acid synthetic peptide based on a sequence found in a gastric protein.
TB-500 is a synthetic peptide modeled on the actin-binding region of thymosin beta-4. See BPC-157 vs TB-500 for how those two compare.

The name is informal. It is a supplier naming convention, not a pharmacopeial or regulatory term, so the per-peptide split inside a GLOW vial varies from supplier to supplier.

What is the KLOW peptide blend?

KLOW keeps all three GLOW components and adds KPV as a fourth. The “K” is generally read as a nod to KPV. Like GLOW, it is sold as one lyophilized vial, and the amount of each peptide is set by the supplier.

Because KLOW carries four peptides instead of three, every quality question gets one step harder: four identities to confirm, four quantities to match against the label, and more chances for one component to be under-filled.

KLOW vs GLOW: side-by-side comparison

	GLOW	KLOW
Components	GHK-Cu, BPC-157, TB-500	GHK-Cu, BPC-157, TB-500, KPV
Number of peptides	3	4
Extra component	None	KPV (Lys-Pro-Val)
Main preclinical research themes	Tissue and skin remodeling models	Same, plus inflammation models
Components the FDA panel backed in July 2026	BPC-157, TB-500	BPC-157, TB-500, KPV
Component still awaiting panel review	GHK-Cu (injectable form)	GHK-Cu (injectable form)
Identities to confirm on the COA	3	4
Typical color	Blue tint (from GHK-Cu)	Blue tint (from GHK-Cu)

Neither blend has been studied as a combination in published research that we are aware of. Each component’s literature stands on its own.

What is KPV, and why was it added?

KPV is a tripeptide (lysine-proline-valine) that matches the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the smallest of the four components by far.

Most published KPV work is preclinical: cell studies and rodent models of gut and skin inflammation. That is the logic behind the blend. GLOW’s components are mostly studied in tissue-remodeling models, and KPV adds an inflammation-research angle to the same vial.

KPV also matters for timing. It was one of the six peptides the FDA’s compounding advisory panel voted to recommend in July 2026, which is a large part of why KLOW searches have climbed since.

Where each KLOW and GLOW component stands after the 2026 FDA vote

Three of KLOW’s four components got a favorable vote in July 2026. The fourth, GHK-Cu, is still waiting for its turn.

Component	2026 status	Vote
BPC-157	Panel recommended adding it to the 503A bulks list, July 23	8 yes, 6 no, 1 abstain
TB-500	Panel recommended, July 23	8 yes, 6 no, 1 abstain
KPV	Panel recommended, July 23	8 yes, 6 no, 1 abstain
GHK-Cu (injectable)	On the agenda for the panel’s next meeting, due before the end of February 2027	Not yet voted

Three points the headlines often miss:

A panel vote is not FDA approval. The FDA still has to accept the recommendation and run a notice-and-comment rulemaking. Until then, none of these peptides is formally on the list.
The vote concerns compounding pharmacies. It covers what licensed pharmacies may prepare for a prescription. It does not change anything for research-use-only materials, which sit outside that system entirely (what research use only means).
Blends are not reviewed as blends. The FDA’s process looks at single bulk substances. There is no FDA position on GLOW or KLOW as combinations.

For the five peptides up next, including GHK-Cu, see the FDA’s next peptide review.

What to check on a KLOW or GLOW certificate of analysis

A single-peptide COA answers one question per test. A blend COA has to answer it three or four times. Before you trust a blend vial, confirm:

Every component is identified. Mass spectrometry should show the expected mass for each peptide, not just the largest one.
Every component is quantified. The COA should list an amount per peptide, and each should match the label.
Purity is reported per peak. One overall purity number for a four-peptide mix tells you very little.
Net peptide content is stated. Purity and net content are different numbers; here’s why that matters.
The lot number matches your vial, and the testing lab and test date are named.

New to reading these reports? Start with how to read a peptide COA.

KLOW vs GLOW: frequently asked questions

Is KLOW the same as GLOW?

No. KLOW contains everything in GLOW (GHK-Cu, BPC-157, TB-500) plus a fourth peptide, KPV.

What does the K in KLOW stand for?

It is generally read as a reference to KPV, the peptide KLOW adds to the GLOW formula.

Is KLOW or GLOW FDA approved?

No. Neither blend, and none of its components, is an FDA-approved drug. The July 2026 panel vote was a non-binding recommendation about compounding, not an approval.

Why is GLOW and KLOW powder blue?

The blue tint comes from GHK-Cu, which is a copper complex. A faint blue or blue-green cake is expected in any blend that contains it.

Which is better, KLOW or GLOW?

Neither is better in general. They answer different research questions: KLOW suits work that includes an inflammation angle, GLOW suits work that does not. No published study compares the two blends head to head.